Stock Photo - A drug approved to treat a severe form of asthma has accelerated the health of people with rare chronic immune disorders called hypereosinophilic syndromes (HES) for whom other treatments were ineffective or intolerable. This discovery stems from a small clinical trial by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and conducted through a partnership with global biopharmaceutical company AstraZeneca. The results were published online April 3, 2019 in the New England Journal of Medicine.

@ 0.025 --> Keywords launching task... @ 0.025 --> GetKeywords: Getting cache @ 0.037 --> _srcset calculated @ 0.059 --> begin dades json... @ 0.066 --> begin waiting GetItemsAsync... @ 0.066 --> GetKeywords: Request cached? True @ 0.108 --> itemsController.Get() completed! @ 0.116 --> pricing done @ 0.116 --> Dades JSON completed! @ 0.116 --> Keywords task start waiting @ 0.139 --> GetKeywords: File obtained @ 0.139 --> GetKeywords: File to Json @ 0.140 --> GetKeywords: DocLastUpdate checked @ 0.140 --> GetKeywords: Cached item @ 0.141 --> GetKeywords: keywords ampliacion @ 0.141 --> Keywords task completed @ 0.154 --> Schema completed @ 0.154 --> Adobe ads... @ 0.154 --> Adobe ads done @ 0.154 --> controller done